Eli Lilly is developing a groundbreaking one-time gene-editing treatment that could permanently lower bad cholesterol and reduce heart disease risk. Bloomberg’s Madison Muller joins Open Interest to break down the science, the risks, and why Lilly is racing to expand beyond obesity drugs into its next major growth era. (Source: Bloomberg)
